Once stopped, the Oxford and AstraZeneca COVID-19 vaccine trials have started again

Oxford also states that in large trials, it is likely that several participants will fall ill and each case should be carefully evaluated to ensure a careful safety assessment.

Several countries other than the UK have also been involved in testing the Oxford vaccine, such as Brazil, South Africa and the UK.

The resumption of clinical trials of the Oxford vaccine also led Brazilian health regulators to agree last Saturday to restart trials on the vaccine after receiving information from AstraZeneca.

Previously, clinical trials of the vaccine were temporarily suspended after a participant developed symptoms of neurological problems. these female volunteers reported symptoms consistent with transverse myelitis, a rare inflammation of the spinal cord.

However, quoted from The Guardian, Pascal Soriot, CEO of AstraZeneca said on Thursday this week that an independent committee was conducting a review whether the disease was caused by a vaccine or not related to it.

“We were unable to disclose medical information about the disease for reasons of confidentiality of the participants,” the developer explained.

“We are committed to the safety of our participants and the highest standards of behavior in our studies and will continue to closely monitor safety.”

– .